Tomas Navratil sold $454K of Glaukos (GKOS)

Executed Sep 11 2025, disclosed Sep 12 2025, 1 day later.

Value, as filed

$454K

5,142 sh across 2 lots

Executed

Sep 11 2025

the trade date, as filed

Disclosed

Sep 12 2025

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Tomas Navratil CHIEF DEVELOPMENT OFFICER profile →

Tomas Navratil (CHIEF DEVELOPMENT OFFICER) filed 6 Form 4 reports in the trailing twelve months (0 purchases, 6 sales), most often in Glaukos Corporation (GKOS). The largest single filing was $10.6M of GKOS (44,436 sh across 4 lots, as filed), executed Oct 30.

The name

GKOS

Glaukos Corporation GKOS · Healthcare · 34 filings in 24 months ticker →

Healthcare · Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Tomas Navratil in GKOS

GKOSSALE Glaukos Corporation $10.6M
44,436 sh across 4 lots
Exec Oct 30
Filed Nov 3 · 9:45 PM ET GKOSSALE Glaukos Corporation $146K
888 sh × $163.93
Exec Oct 5
Filed Oct 7 · 7:07 PM ET GKOSSALE Glaukos Corporation $168K
1,083 sh × $154.88
Exec Sep 25
Filed Sep 28 · 6:23 PM ET GKOSSALE Glaukos Corporation $2.5M
13,734 sh across 2 lots
Exec Aug 28
Filed Sep 1 · 6:24 PM ET GKOSSALE Glaukos Corporation $201K
1,537 sh × $130.68
Exec Jun 16
Filed Jun 18 · 5:30 PM ET GKOSSALE Glaukos Corporation $144K
1,237 sh × $116.72
Exec Apr 10
Filed Apr 14 · 5:30 PM ET GKOSSALE Glaukos Corporation $503K
3,416 sh × $147.14
Exec Feb 14 2025
Filed Feb 19 2025 · 5:30 PM ET